114 related articles for article (PubMed ID: 31265074)
1. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
Wu L; Carlino MS; Brown DA; Long GV; Clifton-Bligh R; Mellor R; Moore K; Sasson SC; Menzies AM; Tsang V; Gunton JE
J Clin Endocrinol Metab; 2024 Apr; 109(5):1301-1307. PubMed ID: 37997380
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Gauci ML; Boudou P; Baroudjian B; Vidal-Trecan T; Da Meda L; Madelaine-Chambrin I; Basset-Seguin N; Bagot M; Pages C; Mourah S; Resche-Rigon M; Pinel S; Sassier M; Rouby F; Eftekhari P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
Kurihara S; Oikawa Y; Nakajima R; Satomura A; Tanaka R; Kagamu H; Shimada A
J Diabetes Investig; 2020 Jul; 11(4):1006-1009. PubMed ID: 31926048
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
8. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
9. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
Lowe JR; Perry DJ; Salama AK; Mathews CE; Moss LG; Hanks BA
J Immunother Cancer; 2016; 4():89. PubMed ID: 28031819
[TBL] [Abstract][Full Text] [Related]
10. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
11. Efforts to screen kids for type 1 diabetes multiply.
Couzin-Frankel J
Science; 2024 Mar; 383(6688):1164-1165. PubMed ID: 38484068
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Quandt Z; Young A; Anderson M
Clin Exp Immunol; 2020 May; 200(2):131-140. PubMed ID: 32027018
[TBL] [Abstract][Full Text] [Related]
14. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
15. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus induced by immune checkpoint inhibitors.
Zheng Z; Liu Y; Yang J; Tan C; Zhou L; Wang X; Xiao L; Zhang S; Chen Y; Liu X
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3366. PubMed ID: 32543027
[TBL] [Abstract][Full Text] [Related]
17. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Kyriacou A; Melson E; Chen W; Kempegowda P
Clin Med (Lond); 2020 Jul; 20(4):417-423. PubMed ID: 32675150
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
19. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
20. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]